Sign in Subscribe
Pharmaceutical industry

Rhone-Poulenc Rorer Receives FDA Approval for Taxotere

Strategic Insights

— 2 min read

Rhone-Poulenc Rorer Inc. has received an approvable letter from the US Food and Drug Administration (FDA) for Taxotere, a new anticancer agent for the treatment of patients with locally advanced or metastatic breast cancer whose cancer has progressed during anthracycline-based therapy or has relapsed during adjuvant anthracycline-based therapy. This approval marks the final step before a product receives FDA clearance for marketing in the US, with the company working closely with the FDA to rapidly secure full approval. The FDA's Oncologic Drugs Advisory Committee (ODAC) had unanimously recommended approval of Taxotere on October 17, 1995.

Taxotere has been studied extensively in clinical trials involving over 2,500 patients worldwide and has shown promising results in inhibiting cancer cell division by essentially "freezing" the cell's internal skeleton, which is made up of microtubules. This action can lead to cancer cell death, making it a valuable treatment option for patients with advanced breast cancer.

The approval of Taxotere is significant, given the unmet medical need for effective treatments in the most advanced stages of breast cancer. According to estimates, every hour five women in the US die from breast cancer, with a total of 46,000 women per year succumbing to the disease. Taxotere's approval provides a new hope for these patients.

Key Takeaways:

  • Taxotere has received an approvable letter from the FDA for the treatment of patients with locally advanced or metastatic breast cancer whose cancer has progressed during anthracycline-based therapy or has relapsed during adjuvant anthracycline-based therapy.
  • The FDA's Oncologic Drugs Advisory Committee (ODAC) had unanimously recommended approval of Taxotere on October 17, 1995.
  • Taxotere promotes the assembly and blocks the disassembly of microtubules, essential for cancer cell division, leading to cancer cell death.
  • Over 2,500 patients have been studied in clinical trials worldwide, demonstrating Taxotere's efficacy and safety.
  • The approval of Taxotere marks a significant step in addressing the unmet medical need for effective treatments in advanced breast cancer.
  • Rhone-Poulenc Rorer has invested over $600 million in research and development in the past year.

Statistics:

  • Approximately 182,000 new breast cancer cases are diagnosed in the US each year.
  • Every hour, five women in the US die from breast cancer, totaling 46,000 women per year.
  • Only 10 percent of women with the most advanced stage of breast cancer (Stage IV) are alive five years later.
  • Over 2,500 patients have been studied in clinical trials worldwide for Taxotere.

Sources:

  • PRNewswire, "Rhone-Poulenc Rorer Receives FDA Approval for Taxotere" (October 30, 1995)
  • Rhone-Poulenc Rorer press release (no date)
  • FDA Oncologic Drugs Advisory Committee (ODAC) meeting minutes (October 17, 1995)
  • National Cancer Institute (no date)

Read more